QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

NTLA

QT63Intellia Therapeutics, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
15.67
+0.47+3.09%
OverviewShort InterestFilings
NTLAQT63Intellia Therapeutics, Inc.·NASDAQ
OverviewShort InterestFilings
15.67+3.09%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-3.54
Insider Own3.00%
Shs Outstand139.72M
Perf Week26.88%
Market Cap1.71BForward P/E-EPS next Y-1.85Insider Trans0.05%Shs Float-Perf Month31.24%
Enterprise Value1.65BPEG-EPS next Q-0.80Inst Own-Short Float-Perf Quarter19.16%
Income-373696959.00P/S25.81EPS this Y9.03%Inst Trans-Short Ratio-Perf Half Y71.82%
Sales66.09MP/B2.90EPS next Y42.56%ROA-52.00%Short Interest-Perf YTD74.30%
Book/sh4.44P/C-EPS next 5Y-ROE-57.27%52W High28.25 -44.53%Perf Year63.57%
Cash/sh2.69P/FCF-EPS past 3/5Y-ROIC-59.98%52W Low7.95 97.11%Perf 3Y-
Dividend Est.-EV/EBITDA-4.29Sales past 3/5Y9.35% 3.23%Gross Margin-153.74%Volatility7.80% 6.05%Perf 5Y-
Dividend TTM-EV/Sales24.99EPS Y/Y TTM32.38%Oper. Margin-636.56%ATR (14)1.30Perf 10Y-
Dividend Ex-Date-Quick Ratio6.10Sales Y/Y TTM13.79%Profit Margin-597.04%RSI (14)61.82Recom2.53
Dividend Gr. 3/5Y-Current Ratio6.10EPS Q/Q26.36%SMA2015.94%Beta2.48Target Price26.13
Payout0.00%Debt/Eq0.13Sales Q/Q-11.76%SMA5013.89%Rel Volume1.24Prev Close15.20
Employees403LT Debt/Eq0.10EarningsAug 06SMA20016.35%Avg Volume7.11MPrice15.67
IPO DateMay 06, 2016Option/ShortYes / YesEPS/Sales Surpr.11.96% 7.14%Net Debt/EBITDA0.14Volume8,842,640Change3.09%
Analyst Ratings
DateActionAnalystRatingTarget
Jun-15-26ReiteratedNew Street$25
May-13-26ReiteratedBernsteinMarket Perform$15 → $17
May-12-26ReiteratedCanaccord GenuityBuy$49
Apr-27-26ReiteratedLeerink PartnersOutperform$29 → $35
Apr-27-26ReiteratedRobert W. Baird$7.00 → $13
Apr-27-26ReiteratedChardan CapitalBuy$48 → $30
Mar-04-26UpgradeJones TradingHold → Buy
Jan-28-26ReiteratedKeyBanc$25
Jan-27-26ReiteratedRobert W. Baird$9.00 → $7.00
Nov-12-25DowngradeWolfe ResearchOutperform → Peer Perform
Latest News
Jun-17-26
Jun-17-2610:11AM
Jabil Posts Upbeat Q3 Results, Joins Uniqure, Braiin And Other Big Stocks Moving Higher On WednesdayBenzinga
Jun-15-26
Jun-15-2610:09AM
Citizens Reiterates Market Outperform on Intellia Therapeutics, Maintains $30 Price TargetBenzinga
09:47AM
Wedbush Reiterates Neutral on Intellia Therapeutics, Maintains $12 Price TargetBenzinga
09:39AM
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling DisorderBenzinga
06:15AM
HC Wainwright & Co. Reiterates Buy on Intellia Therapeutics, Maintains $25 Price TargetBenzinga
03:18AM
Reported Saturday, Intellia Therapeutics' Lonvo-z Achieves 87% Attack Reduction And 62% Attack-Free Rate In Phase 3 HAELO Trial With Results Published Simultaneously In New England Journal Of MedicineBenzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue666858
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A1681610
Gross Profit-1015248
Selling, General and Administrative Excl. Other158120126
Research and Development362389466
Other Operating Expense-201-16-10
Operating Income-421-441-534
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-26-28-15
Net Income Before Taxes-394-413-519
Income Taxes
000
Consolidated Net Income-394-413-519
Net Income From Continuing Operations-394-413-519
Net Income-394-413-519
EPS (Recurring)-3.54-3.81-5.25
EPS (Basic, Before Extraordinaries)-3.54-3.81-5.25
EPS (Diluted)-3.54-3.81-5.25
EBITDA-384-397-509
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio28.0214.28—
Gross Margin-153.0376.4782.76
Operating Margin-637.88-648.53-920.69
Net Margin-596.97-607.35-894.83
Shares Outstanding11810899
Market Capitalization1,849971—
Operating Lease Expense
———
Insider Trading Volume
$16.44$15.10$13.75$12.41$11.07● Close Price0.00M0.35M0.70M1.05M1.40MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
BASTA JAMESEVP, General CounselMar 02 '26Sale13.781,21116,688156,794Mar 03 12:00 AM
Clark ElianaEVP, Chief Technical OfficerMar 02 '26Sale13.786078,36493,864Mar 03 12:00 AM
BASTA JAMESEVP, General CounselJan 05 '26Sale9.2110,39795,756101,528Jan 07 12:00 AM
Cohen Fred EDirectorJan 05 '26Buy9.35150,0001,402,500207,453Jan 07 12:00 AM
LEONARD JOHN MPresident and CEOJan 05 '26Sale9.2134,146314,4851,013,339Jan 07 12:00 AM
Lebwohl DavidEVP, Chief Medical OfficerJan 05 '26Sale9.2111,903109,627121,249Jan 07 12:00 AM
Dube Michael PVP, Chief Accounting OfficerJan 05 '26Sale9.212,98927,52952,277Jan 07 12:00 AM
Schultes Birgit CEVP, Chief Scientific OfficerJan 05 '26Sale9.218,50878,35998,533Jan 07 12:00 AM
Clark ElianaEVP, Chief Technical OfficerJan 05 '26Sale9.219,51587,63387,118Jan 07 12:00 AM
Dulac Edward J IIIEVP, Chief Financial OfficerJan 05 '26Sale9.216,37958,75199,683Jan 07 12:00 AM
LEONARD JOHN MPresident and CEODec 12 '25Option Exercise6.8317,114116,8881,047,485Dec 12 12:00 AM
LEONARD JOHN MPresident and CEODec 11 '25Sale9.4988,146836,3841,038,928Dec 12 12:00 AM
LEONARD JOHN MPresident and CEODec 11 '25Option Exercise6.8399,918682,4401,127,074Dec 12 12:00 AM
Schultes Birgit CEVP, Chief Scientific OfficerOct 01 '25Sale17.3831539105,184Oct 03 12:00 AM
Dube Michael PVP, Chief Accounting OfficerOct 01 '25Sale17.381,87132,51855,266Oct 03 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR